読み込み中
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
前日終値
$2.13
−$0.01 · -0.47%
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
68
割安
センチメント
53
まちまち
リスク
69
高リスク
モメンタム
57
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
日中レンジ
現在 $2.13
52週レンジ
現在 $2.13
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1.49億 USD | 7489万 USD | 7134.8万 USD | 6520.6万 USD | 5531.2万 USD |
| 売上原価 | 7684.9万 USD | 2072.9万 USD | 1964.3万 USD | 1548.3万 USD | 1165.3万 USD |
| 粗利益 | 7230.8万 USD | 5416.1万 USD | 5170.5万 USD | 4972.3万 USD | 4365.9万 USD |
| 研究開発 | 658.4万 USD | 1277.1万 USD | 951.5万 USD | 933.6万 USD | 792.3万 USD |
| 販売・一般管理 | 9716万 USD | 7595.3万 USD | 7274.4万 USD | 7549.8万 USD | 6330万 USD |
| 営業費用 | 1.04億 USD | 8872.4万 USD | 8225.9万 USD | 8483.4万 USD | 7122.3万 USD |
| 受取利息 | — | — | 2.4万 USD | — | — |
| 支払利息 | 841.5万 USD | 728.6万 USD | 542.4万 USD | 360万 USD | 330万 USD |
| 減価償却費と償却費 | 346.5万 USD | 207.3万 USD | 200.6万 USD | 164.8万 USD | 106万 USD |
| 営業利益 | −3143.6万 USD | −3456.3万 USD | −3055.4万 USD | −3511.1万 USD | −2756.4万 USD |
| 純利益 | −3899.8万 USD | −4370.8万 USD | −3018.9万 USD | −3715.9万 USD | −3119.3万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$5.00
上昇余地（134.74%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI300.04万0.00%2.3兆 USD0.03%$381.94+0.63%
AdvisorShares Psychedelics ETFPSIL182.89万3.90%4685.29万 USD1.84%$21.765+3.69%
Vanguard Extended Market ETFVXF136.03万0.00%954億 USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC19.21万0.01%13.17億 USD0.60%$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM19万0.16%1.17億 USD0.73%$15.9402+0.25%
Invesco NASDAQ Future Gen 200 ETFQQQS8.99万0.40%2275.83万 USD0.20%$42.145+1.39%Vanguard Morningstar Total Stock Market ETFVTIAdvisorShares Psychedelics ETFPSILVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMInvesco NASDAQ Future Gen 200 ETFQQQSAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
